Integra LifeSciences (NASDAQ:IART) Sets New 12-Month Low at $21.33

Integra LifeSciences Holdings Co. (NASDAQ:IART) hit a new 52-week low on Monday . The stock traded as low as $21.33 and last traded at $21.40, with a volume of 32840 shares traded. The stock had previously closed at $21.80.

Wall Street Analyst Weigh In

IART has been the subject of a number of analyst reports. Morgan Stanley increased their price target on Integra LifeSciences from $24.00 to $27.00 and gave the company an “underweight” rating in a report on Monday, July 15th. Oppenheimer downgraded Integra LifeSciences from an “outperform” rating to a “market perform” rating in a report on Tuesday, May 7th. Citigroup downgraded Integra LifeSciences from a “neutral” rating to a “sell” rating and reduced their price target for the company from $30.00 to $23.00 in a report on Tuesday, July 30th. Truist Financial reduced their target price on Integra LifeSciences from $32.00 to $26.00 and set a “hold” rating on the stock in a report on Tuesday, July 30th. Finally, Wells Fargo & Company downgraded Integra LifeSciences from an “overweight” rating to an “equal weight” rating and reduced their target price for the stock from $45.00 to $25.00 in a report on Tuesday, May 7th. Four research analysts have rated the stock with a sell rating, four have given a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat, Integra LifeSciences currently has a consensus rating of “Hold” and an average target price of $29.25.

Integra LifeSciences Stock Down 2.3 %

The firm has a market capitalization of $1.68 billion, a P/E ratio of 43.60, a price-to-earnings-growth ratio of 0.84 and a beta of 1.11. The business has a 50 day moving average price of $28.68 and a 200 day moving average price of $32.44. The company has a debt-to-equity ratio of 1.17, a current ratio of 3.39 and a quick ratio of 3.35.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings results on Monday, July 29th. The life sciences company reported $0.63 earnings per share for the quarter, topping analysts’ consensus estimates of $0.62 by $0.01. Integra LifeSciences had a net margin of 1.51% and a return on equity of 14.07%. The company had revenue of $418.20 million for the quarter, compared to analysts’ expectations of $413.07 million. During the same period last year, the firm posted $0.71 earnings per share. The business’s quarterly revenue was up 9.7% compared to the same quarter last year. On average, analysts predict that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current year.

Insider Buying and Selling

In other Integra LifeSciences news, Chairman Stuart Essig bought 52,641 shares of the business’s stock in a transaction on Thursday, May 23rd. The stock was purchased at an average cost of $28.49 per share, for a total transaction of $1,499,742.09. Following the completion of the purchase, the chairman now directly owns 487,922 shares of the company’s stock, valued at $13,900,897.78. The acquisition was disclosed in a filing with the SEC, which is available at this link. 3.10% of the stock is currently owned by insiders.

Institutional Trading of Integra LifeSciences

A number of institutional investors and hedge funds have recently modified their holdings of the business. Dimensional Fund Advisors LP boosted its holdings in shares of Integra LifeSciences by 0.7% in the second quarter. Dimensional Fund Advisors LP now owns 1,785,009 shares of the life sciences company’s stock worth $52,014,000 after acquiring an additional 12,766 shares during the period. GHP Investment Advisors Inc. boosted its holdings in shares of Integra LifeSciences by 3.8% in the second quarter. GHP Investment Advisors Inc. now owns 67,682 shares of the life sciences company’s stock worth $1,972,000 after acquiring an additional 2,498 shares during the period. Headlands Technologies LLC boosted its holdings in shares of Integra LifeSciences by 458.2% in the second quarter. Headlands Technologies LLC now owns 26,592 shares of the life sciences company’s stock worth $775,000 after acquiring an additional 21,828 shares during the period. Choreo LLC bought a new position in shares of Integra LifeSciences in the second quarter worth $336,000. Finally, Cooke & Bieler LP boosted its holdings in shares of Integra LifeSciences by 12.4% in the second quarter. Cooke & Bieler LP now owns 3,514,281 shares of the life sciences company’s stock worth $102,406,000 after acquiring an additional 388,710 shares during the period. 84.78% of the stock is owned by hedge funds and other institutional investors.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.